Cargando…

Correction: Exploiting the promiscuity of imatinib

Detalles Bibliográficos
Autores principales:	Lee, Shun J, Wang, Jean YJ
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2010
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2893136/ http://dx.doi.org/10.1186/1741-7007-8-82

Ejemplares similares

Exploiting the promiscuity of imatinib
por: Lee, Shun J, et al.
Publicado: (2009)

Correction: Drug Promiscuity in PDB: Protein Binding Site Similarity Is Key
por: Haupt, V. Joachim, et al.
Publicado: (2013)

Correction to: Lost in promiscuity? An evolutionary and biochemical evaluation of HSD10 function in cardiolipin metabolism
por: Wohlfarter, Yvonne, et al.
Publicado: (2023)

Correction: Tumor Volume as an Alternative Response Measurement for Imatinib Treated GIST Patients
por: Schiavon, Gaia, et al.
Publicado: (2013)

Exploiting Substrate Promiscuity of Ectoine Hydroxylase for Regio- and Stereoselective Modification of Homoectoine
por: Czech, Laura, et al.
Publicado: (2019)

Correction: The Exploration-Exploitation Dilemma: A Multidisciplinary Framework
Publicado: (2015)

Exploiting the Substrate Promiscuity of Hydroxycinnamoyl-CoA:Shikimate Hydroxycinnamoyl Transferase to Reduce Lignin
por: Eudes, Aymerick, et al.
Publicado: (2016)

Correction: Formulation and In Vitro, In Vivo Evaluation of Effervescent Floating Sustained-Release Imatinib Mesylate Tablet
Publicado: (2022)

Correction: Birds of a Feather: Neanderthal Exploitation of Raptors and Corvids
por: Finlayson, Clive, et al.
Publicado: (2012)

Molecular mechanism of SbmA, a promiscuous transporter exploited by antimicrobial peptides
por: Ghilarov, Dmitry, et al.
Publicado: (2021)

Correction: Exploiting the Adaptation Dynamics to Predict the Distribution of Beneficial Fitness Effects
Publicado: (2016)

Correction: Real-Time Analysis of Imatinib- and Dasatinib-Induced Effects on Chronic Myelogenous Leukemia Cell Interaction with Fibronectin
Publicado: (2014)

Correction: Wogonin induces cell cycle arrest and erythroid differentiation in imatinib-resistant K562 cells and primary CML cells
por: Yang, Hao, et al.
Publicado: (2020)

Correction: Patil, A. et al. Hub Promiscuity in Protein-Protein Interaction Networks. Int. J. Mol. Sci. 2010, 11, 1930-1943
por: Patil, Ashwini, et al.
Publicado: (2010)

Correction: Imatinib and Nilotinib Reverse Multidrug Resistance in Cancer Cells by Inhibiting the Efflux Activity of the MRP7 (ABCC10)
por: Shen, Tong, et al.
Publicado: (2009)

Correction: Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours
por: Serrano, César, et al.
Publicado: (2019)

Exploiting Mitochondrial Dysfunction for Effective Elimination of Imatinib-Resistant Leukemic Cells
por: Kluza, Jérome, et al.
Publicado: (2011)

Correction: Aclacinomycin A Sensitizes K562 Chronic Myeloid Leukemia Cells to Imatinib through p38MAPK-Mediated Erythroid Differentiation
por: Lee, Yueh-Lun, et al.
Publicado: (2017)

Correction: Exploitation of Insect Vibrational Signals Reveals a New Method of Pest Management
Publicado: (2014)

Correction: Imatinib mesylate inhibits STAT5 phosphorylation in response to IL-7 and promotes T cell lymphopenia in chronic myelogenous leukemia patients
por: Thiant, S., et al.
Publicado: (2020)

Correction to: Real‑world imatinib mesylate treatment in patients with chronic myeloid leukemia: The importance of molecular monitoring and the early molecular response
por: Ferreira, Amanda Pifano Soares, et al.
Publicado: (2023)

Author Correction: Hyaluronan abrogates imatinib-induced senescence in chronic myeloid leukemia cell lines
por: Lompardía, Silvina, et al.
Publicado: (2020)

Correction: In it for the long run: perspectives on exploiting long-read sequencing in livestock for population scale studies of structural variants
por: Nguyen, Tuan V., et al.
Publicado: (2023)

Publisher Correction: The genetic legacy of extreme exploitation in a polar vertebrate
por: Paijmans, Anneke J., et al.
Publicado: (2020)

Correction: Picomolar Inhibition of Plasmepsin V, an Essential Malaria Protease, Achieved Exploiting the Prime Region
por: Gambini, Luca, et al.
Publicado: (2016)

Correction: CM363, a novel naphthoquinone derivative which acts as multikinase modulator and overcomes imatinib resistance in chronic myelogenous leukemia
por: Guerra, Borja, et al.
Publicado: (2018)

Correction: Melioidosis Vaccines: A Systematic Review and Appraisal of the Potential to Exploit Biodefense Vaccines for Public Health Purposes
por: Peacock, Sharon J., et al.
Publicado: (2013)

Author Correction: An open data infrastructure for the study of anthropogenic hazards linked to georesource exploitation
por: Orlecka-Sikora, Beata, et al.
Publicado: (2020)

Correction: Imatinib Ameliorates Neuroinflammation in a Rat Model of Multiple Sclerosis by Enhancing Blood-Brain Barrier Integrity and by Modulating the Peripheral Immune Response
por: Z. Adzemovic, Milena, et al.
Publicado: (2013)

Correction: Imatinib Ameliorates Neuroinflammation in a Rat Model of Multiple Sclerosis by Enhancing Blood-Brain Barrier Integrity and by Modulating the Peripheral Immune Response
Publicado: (2015)

Correction: An aquatic virus exploits the IL6-STAT3-HSP90 signaling axis to promote viral entry
por: Hou, Guoli, et al.
Publicado: (2023)

Correction to: Survival in advanced GIST has improved over time and correlates with increased access to post-imatinib tyrosine kinase inhibitors: results from Life Raft Group Registry
por: Call, Jerry W., et al.
Publicado: (2019)

Correction to: A cross-sectional study of community perceptions of stigmatization amongst women affected by UN-peacekeeper perpetrated sexual exploitation and abuse
por: Gray, Samantha, et al.
Publicado: (2022)

Correction: The Therapeutic Response of Gastrointestinal Stromal Tumors to Imatinib Treatment Assessed by Intravoxel Incoherent Motion Diffusion-Weighted Magnetic Resonance Imaging with Histopathological Correlation
Publicado: (2017)

Correction: Exploiting MEK Inhibitor-Mediated Activation of ERα for Therapeutic Intervention in ER-Positive Ovarian Carcinoma
por: Hou, June Y., et al.
Publicado: (2016)

Correction: MicroRNA-1301-Mediated RanGAP1 Downregulation Induces BCR-ABL Nuclear Entrapment to Enhance Imatinib Efficacy in Chronic Myeloid Leukemia Cells
por: Lin, Tsung-Yao, et al.
Publicado: (2017)

Target promiscuity and heterogeneous effects of tarantula venom peptides affecting Na(+) and K(+) ion channels.
por: Redaelli, Elisa, et al.
Publicado: (2010)

Correction: Exploiting the transcriptional specificity of the alpha-methylacyl-CoA racemase AMACR promoter for the molecular imaging of prostate cancer
por: Shapovalova, Mariya, et al.
Publicado: (2019)

Correction: MPT0B169, a New Antitubulin Agent, Inhibits Bcr-Abl Expression and Induces Mitochondrion-Mediated Apoptosis in Nonresistant and Imatinib-Resistant Chronic Myeloid Leukemia Cells
por: Wong, Shuit-Mun, et al.
Publicado: (2017)

Promiscuous drugs compared to selective drugs (promiscuity can be a virtue)
por: Mencher, Simon K, et al.
Publicado: (2005)

Cannot write session to /tmp/vufind_sessions/sess_4eutr1e2t16toi68f05ubabsqr